This year’s roundtable (in its 14th year) will focus on metrics + strategies for advancing bioethics, patient-centricity + health equity across the bio-pharmaceutical sector and amplifying + connecting participants’ work in these areas. Discussions may inform agenda-setting + metrics development for the Good Pharma Scorecard. Sessions will begin w/ opening remarks + transition to open discussion.
When: September 15, 2023 8am-3pm
Where: E&Y NYC Offices
Register here
——————————— Agenda ———————————-
8-8:30am Coffee + Registration
8:30-8:45 Welcome + Keynote. Yele Aluko, Chief Medical Officer, EY Americas
8:45-9am Setting the Stage: Why we are here and what we hope to accomplish
- Lauren Rogge, Principle, Climate Change and Sustainability, EY
- Jennifer Miller, Co-Director, Program for Biomedical Ethics, Associate Professor, Yale School of Medicine; President, Bioethics International; Good Pharma Scorecard
9-10:30 Clinical Trial Diversity
This session will discuss metrics and strategies for advancing diversity and inclusion in clinical research and what we can + should hope to see by 2025. We will start with catalyst speakers + move to open discussion with all roundtable participants.
- Moderator: Jennifer Miller, Co-Director, Program for Biomedical Ethics, Associate Professor, Yale; Founder, Bioethics International, Good Pharma Scorecard
- Judy Ngang, Executive Director, Representation in Clinical Research, Amgen
- Sandra Amaro, Head of Clinical Trial Diversity, Pfizer
- Yasmeen Long, Faster Cures
- Brittany Gerald, Clinical Trial Diversity and Inclusion, Moderna
- Maria Apostolaros, Deputy VP, Science and Regulatory Advocacy, PhRMA
- Martin Mendoza, Director, Health Equity for the All of Us Research Program, NIH
- Salman Shah, R&D Leader, EY
- Lorena Kuri, Head, Diversity Strategy, BMS
- Meghan McKenzie, Principal, Patient Inclusion & Health Equity, Genentech
- Ashley, Citeline
10:30-11:30 Health Equity + the Role of Pharma
This panel will discuss strategies of pharmaceutical leaders in advancing health equity for US patients, metrics for benchmarking success, and what we can/should hope to see by 2025.
- Moderator: Yele Aluko, Chief Medical Officer, EY Americas
- Cassandra Smith, Advocacy Relations Director, Amgen
- Amrit Ray, Hastings Center, Board Member; Life Sciences Corporate Board Director; Former Global President, R&D and Medical, Pfizer
- Marisa Greenwald, Healthcare Strategy Leader, EY Parthenon
- Pierre Theodore, Executive Director of Health Equity and Patient Inclusion, Roche
11:30-12pm The Bioethics Leadership Forum
- Missy Heidelberg, Global Bioethics Lead, Takeda
- Marc Wilenzick, Associate General Counsel, Gilead
- David Leventhal, Enterprise Clinical Trial Data Sharing Lead, Pfizer
- Jessica Scott, CEO, Legacy Health
- Kim Sabelko, Susan G. Komen Foundation
12-12:15 Break + grab lunch for working lunch
12:15-1 Global Health Equity: Priority setting in research agendas + access to medicines
- Moderator Rob Scott, former CMO, AbbVie
- Leo Russo, Head of Global Medical Epidemiology, Pfizer
- Lauren Puffer, Director of Sustainability Banking / ESG, Cowen
- Muna Tuna, Partner, Market Access, Pricing and Reimbursement, EY
- Carmen Villar, VP Social Business Innovation, ESG, Global Impact Giving, and Enterprise Health Equity, Merck
- Tania Small, VP Global Medical Oncology, Chair, R&D Leadership Team DEI Council, GSK
1-1:45pm Patient Engagement + Return of Value to Participants in Trials: Metrics for success
The importance of patient engagement + patient focused drug development have received a lot of attention over the decades, yet metrics for success remain undefined. We will discuss where Pharma is today on engaging patients and building real patient-centric business models, what’s missing, and how we measure and track progress.
- Moderator: Martin Mendoza, Director, Health Equity, All of Us Research, NIH
- Melissa Penn, Director Patient Engagement R&D, Bayer
- Cynthia Grossman, Head, Real-world Research Networks and Pioneering Personalized & Digital Medicine in Neuroscience, Biogen
- Wendy Erler, Global Head Patient Experience, Patient Advocacy & Patient and Caregiver Insights, AstraZeneca
- Rachael Eckles, Senior Director, Public Policy and Oncology Policy, BMS
- David Leventhal, Enterprise Clinical Trial Data Sharing Lead, Pfizer
1:45-2:15 ESG, Social Impact + Financial Considerations: Can companies do well by doing good?
This panel will explore investor expectations of reporting on the biopharma-specific social dimensions of ESG along with challenges associated with developing standardized metrics. This will also explore the role the Good Pharma Scorecard in driving consistency in reporting on social-responsibility issues in the biopharma innovation portfolio.
- Moderator: Mohit Bhargava, Partner, EY
- Byron Austin, Head, Corporate Responsibility and ESG Management, Organon
- Jessica Daly, Director, ESG Strategy & Engagement, Merck
2:15-2:25 Circling Back: Next Steps for Participants as Agents of Change
2:25-2:55 Full Group Discussion: Priority Setting + Next Steps for Metrics Development
Full group discussion on key take-aways, next steps, and themes we want to translate into action and lean into over the next 12 months.
- Moderator: Jeremy Abbate, Publisher, Scientific American
2:55-3pm Closing Remarks
- Jennifer Miller, Yale; Bioethics International; Good Pharma Scorecard
- Yele Aluko, Chief Medical Officer, EY Americas
- Lauren Rogge, Principle, Climate Change and Sustainability, EY
Hosts: Bioethics International, EY, Yale Program for Biomedical Ethics
Sponsors: EY, Yale Program for Biomedical Ethics, Bioethics International, Citeline